AI plays tetris with proteins

AI powered drug discovery

Scroll Down

What we do

Peptris is an AI-powered preclinical drug discovery company

Pharma R&D efficiency is decreasing steadily, while the cost of new drug discovery is increasing exponentially. Vast amounts of structured data are being generated using high throughput technologies in drug discovery/development. However, the analysis and interpretation of this data for meaningful outcomes has been a challenge.

Peptris has developed a platform technology to enhance efficiencies across the drug discovery/development cascade using Artificial Intelligence/Machine Learning

Peptris’ proprietary AI platform integrates unsupervised learning and generative AI to design optimized molecules, significantly reducing the need for wet lab testing. The automated platform streamlines this process, designing potent, safe, selective, and biologically active drug candidates. The platform has been used to discover Novel Chemical Entities (NCE), to repurpose or reposition approved drugs, and rescue molecules that have been proven safe in the clinic. We have a pipeline of preclinical assets that have been discovered, validated in vitro and in vivo disease models.

Peptris operates virtually, focusing on AI-driven discovery while outsourcing wet lab work to CROs and biotech partners. Revenue comes from licensing deals, milestone payments, and royalties, with partnerships across academia, biotech and pharma companies and rare disease organizations

Novel Chemical Entity

Generate novel scaffolds and molecules that can be sythesised, with superior activity, selectivity and optimal drug like properties

Repurpose Approved Drugs

Repurpose approved drugs and molecules with proven clinical safety to find solutions for unmet medical needs and rare disease indications. This will help reach the patient early as it fast tracks the preclinical and clinical development process.

Rescue Clinical Candidates

Identify novel molecular targets and disease indications for clinically safe molecules that have passed Phase I or later stages but not developed further due to reasons including efficacy in primary disease indication or lack of commercial potential

Technology

We Accelerate Drug Discovery

Our proprietary technology leverages cutting edge neural network architectures found in Natural Language Processing, Large Language Models and Image processing research areas.

Peptris has created an array of AI models to understand the chemical space and generate novel molecules and predict varied parameters that are critical for a molecule to be considered a potential drug candidate. The power of the Peptris platform is derived from a foundational unsupervised learning algorithm to understand the vast chemical space. It uses a large language model built on a novel and proprietary molecule language syntax. The foundational model learns from ultra-large and diverse purchasable compound libraries and predicts various drug-like properties with precision

fantastic_four

Our proprietary generative AI algorithms can also design novel molecules with superior physicochemical properties and drug target activity. The models are orchestrated by an automated process that prunes large purchasable compound datasets and creates de novo variations of compounds that are predicted to be novel, potent, safe, selective, and biologically active. Our neural network models when benchmarked for various molecule property predictions, show a high generalization power enabling faster candidate identification.

Features

The Peptris Advantage

Novel

Generates diverse, patentable and synthesizable molecules that are potent, selective, safe and biologically active

Fast

Leverages the power of unsupervised learning to rapidly screen ultra large diverse virtual chemical libraries

Accurate

Predict with accuracy various parameters that are critical for a molecule to be considered a potential drug candidate

Cost Effective

Ensures that the number of molecules to be tested in a wet lab are small, making the discovery process cost effective


Our Progress

Peptris Drug Discovery Pipeline

Peptris Pipeline

About Us

Team

>
Team
Venkatsubramanian
Narayanan

Chief Executive Officer VN
CEO

Specialist in Algorithms. Expertise in building large systems and software. Keen Observer and a great leader

Anand
Budni

Chief Technology Officer AB
CTO

Expert in Image and Video processing and Deep Learning Architectures. The creative thinker and eternal optimist

Shridhar
Narayanan

Chief Strategic Officer SN
CSO

Experienced drug hunter with 18 clinical candidates and one drug in the market. The visionary strategist with a deep mastery of his craft

Amit
Mahajan

Chief Data Scientist AM
CDS

Specialist in fundamental algorithms and prototyping, the analytical thinker passionate about science


Support

Advisors

Dr Frederic Relaix

Dr Frederic Relaix a Professor at the Paris Est-Creteil University (UPEC), director of the Neuroscience research department (ESPRY)., His research group seeks to understand the fundamental mechanisms of development, regeneration and pathology, using skeletal muscle as a model tissue.

Dr Frederic Relaix Scientific Advisor.
Tapan Kumar

Tapan An IIM Ahemadabad Alumnus and Ex-Flipkart VP-Finance, He brings is vast experience in setting up various companies health/food industry. He is our chief financial advisor and guides compay in financial matters and business development

Tapan Kumar Financial Advisor
IIM Ahmadabad Alumni

Our Updates

News and Media

Contact Us

Get in touch

info@peptris.com +919945274057

Where To Find Us

Center for Cellular and Molecular Platforms (C-CAMP),
NCBS-TIFR Campus, GKVK, Bellary Road, Bangalore, India

Follow Us